• Home
  • » 
  • Reports
  • » 
  • Biopharmaceutical Contract Manufacturing Market (2nd Edition) | Industry Analysis | Market Size | 2027

Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017 - 2027

  • Lowest Price Guaranteed From USD 2,499

  • Published
    May 2017

  • Pages
    569

  • View Count
    5829

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 3rd edition

  1. During our research, we came across more than 200 companies offering contract manufacturing services for biopharmaceuticals. These companies possess the capabilities to handle multiple types of biologics; majority of firms offer services related to proteins and peptides (138), antibodies (116), and vaccines (79). Mammalian based manufacturing, the predominant approach, is expected to continue to achieve a relatively higher growth rate in the near future.
  2. Developed regions, such as Europe and North America, currently dominate the biopharmaceutical contract manufacturing landscape. In fact, we identified close to 100 biopharmaceutical manufacturing facilities each, belonging to various players, in both Europe and North America. In addition to the developed regions, we observed that a number of prominent global and indigenous players have facilities (60) based in emerging regions of Asia and rest of the world; examples include (in alphabetical order) BioCell, CinnaGen, Cell Therapies, Concord Biotech, EirGenix, GE Healthcare, Kemwell Biopharma, LuinaBio, Meridian Life Science, Piramal Pharma Solutions, and WuXi AppTec (WuXi Biologics).
  3. During our research, we identified that 69% of all CMOs offer commercial scale manufacturing services; it is also worth highlighting that 27% of all CMOs offer end-to-end services across all scales of operation; examples of such players include 3P Biopharmaceuticals, Batavia Biosciences, CARBOGEN AMCIS, Cobra Biologics and IDT Biologika.
  4. The current global contract biopharmaceutical manufacturing capacity is estimated to be over 3.4 million liters. Established players, such as AbbVie Contract Manufacturing, Celltrion, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung BioLogics and ST Pharm contribute a significant proportion to the overall supply. Having said that, of the over 200 CMOs we evaluated, more than 150 are relatively small or mid-sized companies; such companies are one of the key driving forces behind the heightened pace of biopharmaceutical research and development.
  5. Niche and emerging therapeutic classes hold significant promise for biopharmaceutical CMOs. The rapidly growing development pipeline of antibody drug conjugates and bispecific antibodies (100+ molecules each) are likely to translate into tangible growth opportunities. In addition to antibody based therapeutics, cell and gene therapy manufacturing are other opportunities that are likely to unfold in the near future. CMOs such as 3P Biopharmaceuticals, apceth Biopharma, Batavia Biosciences, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, KBI Biopharma, Meridian Life Science, Waisman Biomanufacturing and WuXi AppTec are actively offering services related to these complex biologics.
  6. As numerous biopharmaceuticals near patent expiry, a wave of follow-on biologics and biosimilars are anticipated to soon enter the market. As of January 2017, there were over 800 biosimilars under development. Upcoming patent expiries of blockbuster therapies, such as infliximab, trastuzumab and adalimumab, are likely to translate into huge growth opportunities for the biosimilars market, which is likely to result in a surge in the demand for contract services providers.
  7. Over 450 deals have been inked in the biopharmaceutical contract manufacturing market in the past decade. Although a significant proportion of these agreements focus on manufacturing (37%), we came across a number of acquisitions / mergers (13%) and specific collaborations (8%) where partner companies have opted to work together in order to significantly expand their respective service portfolios. Several companies have entered into multiple collaborations; these include Lonza (34), CMC Biologics (21), Emergent BioSolutions (20), Charles River Laboratories (19) and Goodwin Biotechnology (18). In addition, multiple players have made significant investments in expanding their existing operations, acquiring new facilities and / or capabilities. We came across more than 150 such instances over the past decade.
  8. Driven by increasing global demand and the rapidly expanding biopharmaceutical market, we expect the overall contract manufacturing market in the biopharmaceuticals domain to grow at an annualized rate of 8.7% between 2017 and 2027. The growth is likely to be higher in emerging markets of Asia and rest of the world.

Report Description

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (HUMIRA, RITUXAN, Lantus, Avastin, Herceptin and REMICADE) and a robust pipeline of product / therapy candidates, the market is poised for significant growth in the coming years. It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics, which are currently under development, and biosimilars, which are generic versions of these biologics. The field continues to witness significant growth in terms of innovation; this activity is clearly indicative of the growing demand for biologics to cater to existing unmet needs in the industry.

It is necessary to highlight the fact that the development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These complications have led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers.

As a result of the above mentioned industry dynamics, the contract manufacturing industry landscape is steadily evolving. CMOs aiming to consolidate their presence in the market are rapidly expanding their service portfolios to provide end-to-end services to their clients and sponsors.

Scope of the Report

The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 - 2027’ report provides an extensive study of the contract manufacturing market for biopharmaceuticals. As the biotechnology industry continues to strive to maximize profits, outsourcing has emerged as a promising trend. The study features in-depth analysis, highlighting capabilities of a diverse set of biopharmaceutical CMOs. In addition to other elements, it provides information on the following:

  • The competitive market landscape and industry analysis based on a number of parameters, such as geographical location, scale of operation, type of biologics manufactured, expression systems used, type of bioreactors used, mode of operation of bioreactors and bioprocessing capacity.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance, information on its manufacturing service and facilities, partnerships and recent developments.
  • A detailed discussion on the key enablers, including certain niche sub-segments, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical contract service providers.
  • A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the market. The analysis takes into consideration the average capacities of small, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research.
  • Information on other aspects of biopharmaceutical outsourcing, which include the growing number of collaborations, partnerships and investments in facility expansions.
  • Affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution.

One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. In order to provide a detailed future outlook, our projections have been segmented on the basis of commonly outsourced business operations (Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs)), types of expression systems and key geographical regions. The base year for the report is 2017, and it provides a detailed market forecast for the period between 2017 and 2027.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. For the purpose of the study, we invited more than 200 senior stakeholders in the industry to participate in a survey. This enabled us to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. In addition, the opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies).

It is worth highlighting that the biopharmaceutical market is characterized by a huge unmet need for adequate manufacturing facilities and expertise. Given the inherent complexities associated with the development of biologics, the aforementioned need is likely to translate into promising business opportunities for CMOs.

Contents

Chapter 2  provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the biopharmaceutical contract manufacturing market and where it is headed in the mid-long term.

Chapter 3  is a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various expression systems used for the development of different biologics and biotherapeutic products. It features a brief overview of contract manufacturing and also includes detailed discussion on the need for outsourcing in this field. We have also presented a list of commonly outsourced biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently associated with the market.

Chapter 4  provides a comprehensive view on the global landscape of biopharmaceutical CMOs. It features an in-depth market review, including regional distribution, analysis by scale of operation, type of biologics manufactured and expression systems. Moreover, the chapter provides information on the production capabilities of CMOs, based on type of bioreactor, mode of operation of bioreactors and fermentation capacity.

Chapter 5  features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the US. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in the US, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 6  features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the Europe. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in Europe, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 7  features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Asia and other regions of the world. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in the aforementioned regions, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 8  focuses on some of the niche segments within the biopharmaceutical industry that are expected to drive the demand for outsourcing in this field. These include ADCs, bispecific antibodies, cell therapies and gene therapies. The chapter provides detailed market overviews, including information on the pipeline, partnerships, investments and the presence of CMOs in each of the aforementioned segments.

Chapter 9  is a case studyfocused on outsourcing of operations related to biosimilars, which represents a major growth opportunity for biopharmaceutical CMOs. It provides an overview of biosimilars and captures information on the various CMOs that are actively involved in this niche market.

Chapter 10  presents an analysis of the recent developments in the biopharmaceutical contract manufacturing market. It provides a detailed list of the various partnerships that have been established in the recent past, along with an overview of other market trends, such as investments and facility expansions.

Chapter 11  features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of biopharmaceutical products. The results of this analysis were used to gain a more accurate understanding of outsourcing capabilities across different geographies. The analysis represents a holistic view on the supply-side of the market, allowing us to present a highly informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 12  presents insights from the survey conducted for this study. We invited over 200 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 13  presents a detailed market forecast for the biopharmaceutical contract manufacturing market segmented by type of business (APIs and FDFs). It features an analysis of the future of biopharmaceutical related outsourcing activities for certain specific geographies across the globe, and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of the market’s evolution, namely the conservative, base and optimistic scenarios.

Chapter 14  provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the contract manufacturing market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 15  is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the biopharmaceutical CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical CMOs.

Chapter 16  contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing domain. In this study, we spoke to Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies).

Chapter 17  is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18  is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. Biopharmaceuticals: An Overview
3.3. Biopharmaceuticals: Manufacturing Process
3.3.1. Types of Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.3.2. Downstream Processing
3.4. Contract Manufacturing: An Overview
3.5. The Need for Outsourcing in the Biopharmaceutical Industry
3.6. Biopharmaceutical Contract Manufacturing: Commonly Outsourced Operations
3.7. Biopharmaceutical Contract Manufacturing: Selecting a CMO Partner
3.8. Biopharmaceutical Contract Manufacturing: Associated Risks and Challenges
 
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.1.1. Geographical Presence of Biopharmaceutical CMOs
4.1.2. Analysis by Types of Biologics
4.1.3. Analysis by Scale of Operation
4.1.4. Analysis by Expression Systems
4.1.5. Analysis by Types of Bioreactors and Modes of Operation
4.1.6. Analysis by Manufacturing Capacity
4.1.7. Analysis by Packaging Form
 
5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
5.1. Chapter Overview
5.2. Biopharmaceutical Outsourcing in North America: Regulatory Scenario
5.2.1. Impact of Current Political Situation
5.3. Leading Biopharmaceutical CMOs in North America
5.3.1. AMRI
5.3.1.1. Company Overview
5.3.1.2. Services Portfolio
5.3.1.2.1. Regulatory Support and Quality Assurance
5.3.1.2.2. Biomanufacturing Services
5.3.1.3. Financial Information
5.3.1.4. Manufacturing Facilities
5.3.1.5. Partnerships
5.3.1.6. Recent Developments
5.3.1.7. Awards and Accolades
5.3.1.8. Future Outlook
 
5.3.2. Baxter BioPharma Solutions
5.3.2.1. Company Overview
5.3.2.2. Services Portfolio
5.3.2.2.1. Biologics Related Services
5.3.2.2.2. Vaccine Related Services
5.3.2.2.3. Regulatory Support
5.3.2.3. Financial Information
5.3.2.4. Manufacturing Facilities
5.3.2.5. Partnerships
5.3.2.6. Recent Developments
5.3.2.7. Awards and Accolades
 
5.3.3. Catalent
5.3.3.1. Company Overview
5.3.3.2. Services Portfolio
5.3.3.2.1. Cell Line Development
5.3.3.2.2. Manufacturing (Biomanufacturing)
5.3.3.2.3. ADCs and Bioconjugates
5.3.3.2.4. Biosimilars
5.3.3.2.5. Analytical Services
5.3.3.2.6. Clinical Supply Services
5.3.3.2.7. Regulatory Support
5.3.3.3. Financial Information
5.3.3.4. Manufacturing Facilities
5.3.3.5. Partnerships
5.3.3.6. Recent Developments
5.3.3.7. Awards and Accolades
5.3.3.8. Future Outlook
 
5.3.4. Cytovance Biologics
5.3.4.1. Company Overview
5.3.4.2. Services Portfolio
5.3.4.2.1. R&D Services
5.3.4.2.2. Manufacturing Services
5.3.4.2.3. Purification and Fill/Finish
5.3.4.3. Manufacturing Facilities
5.3.4.4. Partnerships
5.3.4.5. Recent Developments
5.3.4.6. Awards and Accolades
 
5.3.5. Patheon
5.3.5.1. Company Overview
5.3.5.2. Services Portfolio
5.3.5.2.1. Biologics
5.3.5.2.2. Small Molecules
5.3.5.2.3. Supply Chain Management
5.3.5.3. Financial Information
5.3.5.4. Manufacturing Facilities
5.3.5.5. Partnerships and Acquisitions
5.3.5.6. Recent Developments
5.3.5.7. Awards and Accolades
 
5.4. Biopharmaceutical Contract Manufacturing in North America: Sub-Market Forecast, 2017-2027
5.4.1. Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, 2017-2027
5.4.2. Biopharmaceutical Contract Manufacturing in North America: Distribution by Expression Systems, 2017-2027
 
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
6.1. Chapter Overview
6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario
6.3. Leading Biopharmaceutical CMOs in Europe
6.3.1. 3P Biopharmaceuticals
6.3.1.1. Company Overview
6.3.1.2. Services Portfolio
6.3.1.3. Manufacturing Facilities
6.3.1.4. Partnerships
6.3.1.5. Recent Developments
6.3.1.6. Awards and Accolades
 
6.3.2. Boehringer Ingelheim BioXcellence
6.3.2.1. Company Overview
6.3.2.2. Services Portfolio
6.3.2.3. Financial Information
6.3.2.4. Manufacturing Facilities
6.3.2.5. Partnerships
6.3.2.6. Recent Developments
6.3.2.7. Awards and Accolades
 
6.3.3. Celonic
6.3.3.1. Company Overview
6.3.3.2. Services Portfolio
6.3.3.3. Manufacturing Facilities
6.3.3.4. Partnerships
6.3.3.5. Recent Developments
 
6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.4.1. Company Overview
6.3.4.2. Services Portfolio
6.3.4.3. Financial Information
6.3.4.4. Manufacturing Facilities
6.3.4.5. Partnerships
6.3.4.6. Recent Developments
 
6.3.5. LFB Biopharma
6.3.5.1. Company Overview
6.3.5.2. Services Portfolio
6.3.5.3. Financial Information
6.3.5.4. Manufacturing Facilities
6.3.5.5. Partnerships
6.3.5.6. Recent Developments
 
6.3.6. Lonza
6.3.6.1. Company Overview
6.3.6.2. Services Portfolio
6.3.6.3. Financial Information
6.3.6.4. Manufacturing Facilities
6.3.6.5. Partnerships
6.3.6.6. Recent Developments
 
6.3.7. Menarini Biotech
6.3.7.1. Company Overview
6.3.7.2. Services Portfolio
6.3.7.3. Partnerships
 
6.3.8. Novasep
6.3.8.1. Company Overview
6.3.8.2. Services Portfolio
6.3.8.3. Financial Information
6.3.8.4. Manufacturing Facilities
6.3.8.5. Partnerships
6.3.8.6. Recent Developments
 
6.3.9. Rentschler Biotechnologie
6.3.9.1. Company Overview
6.3.9.2. Services Portfolio
6.3.9.3. Manufacturing Facilities
6.3.9.4. Partnerships
6.3.9.5. Recent Developments
 
6.4. Biopharmaceutical Contract Manufacturing in Europe: Sub-Market Forecast, 2017-2027
6.4.1. Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, 2017-2027
6.4.2. Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, 2017-2027
 
7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA AND THE REST OF THE WORLD
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in China
7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
7.2.2. Challenges Faced by CMOs in China
7.3. Leading Biopharmaceutical CMOs in China
7.3.1. Autotek Bio
7.3.1.1. Company Overview
7.3.1.2. Services Portfolio
7.3.1.3. Manufacturing Facilities
 
7.3.2. WuXi AppTec
7.3.2.1. Company Overview
7.3.2.2. Services Portfolio
7.3.2.3. Financial Information
7.3.2.4. Manufacturing Facilities
7.3.2.5. Partnerships
7.3.2.6. Recent Developments
 
7.4. Biopharmaceutical Contract Manufacturing in China: Sub-Market Forecast, 2017-2027
7.4.1. Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, 2017-2027
7.4.2. Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, 2017-2027
 
7.5. Biopharmaceutical Contract Manufacturing in India
7.5.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario
7.5.2. Challenges Faced by CMOs in India
7.6. Leading Biopharmaceutical CMOs in India
7.6.1. Intas Pharmaceuticals
7.6.1.1. Company Overview
7.6.1.2. Services Portfolio
7.6.1.3. Financial Information
7.6.1.4. Manufacturing Facilities
7.6.1.5. Partnerships
 
7.6.2. Kemwell Biopharma
7.6.2.1. Company Overview
7.6.2.2. Services Portfolio
7.6.2.3. Manufacturing Facilities
7.6.2.4. Partnerships
7.6.2.5. Recent Developments
 
7.6.3. Piramal Pharma Solutions
7.6.3.1. Company Overview
7.6.3.2. Services Portfolio
7.6.3.3. Financial Information
7.6.3.4. Manufacturing Facilities
7.6.3.5. Partnerships
7.6.3.6. Recent Developments
 
7.6.4. Shashun Pharma
7.6.4.1. Company Overview
7.6.4.2. Services Portfolio
7.6.4.3. Financial Information
7.6.4.4. Manufacturing Facilities
7.6.4.5. Partnerships
 
7.6.5. Syngene
7.6.5.1. Company Overview
7.6.5.2. Services Portfolio
7.6.5.3. Financial Information
7.6.5.4. Manufacturing Facilities
7.6.5.5. Partnerships
 
7.7. Biopharmaceutical Contract Manufacturing in India: Sub-Market Forecast, 2017-2027
7.7.1. Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, 2017-2027
7.7.2. Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, 2017-2027
 
7.8. Biopharmaceutical Contract Manufacturing in Japan
7.8.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario
7.8.2. Challenges Faced by CMOs in Japan
7.9. Leading Biopharmaceutical CMOs in Japan
7.9.1. Asahi Glass
7.9.1.1. Company Overview
7.9.1.2. Services Portfolio
7.9.1.3. Financial Information
7.9.1.4. Manufacturing Facilities
7.9.1.5. Partnerships
 
7.10. Biopharmaceutical Contract Manufacturing in Japan: Sub-Market Forecast, 2017-2027
7.10.1. Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, 2017-2027
7.10.2. Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, 2017-2027
 
7.11. Biopharmaceutical Contract Manufacturing in South Korea
7.11.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario
7.11.2. Challenges Faced by CMOs in South Korea
7.12. Leading Biopharmaceutical CMOs in South Korea
7.12.1. DMBio
7.12.1.1. Company Overview
7.12.1.2. Services Portfolio
7.12.1.3. Manufacturing Facilities
7.12.1.4. Recent Developments
 
7.12.2. Samsung BioLogics
7.12.2.1. Company Overview
7.12.2.2. Services Portfolio
7.12.2.3. Financial Information
7.12.2.4. Manufacturing Facilities
7.12.2.5. Partnerships
7.12.2.6. Recent Developments
 
7.13. Biopharmaceutical Contract Manufacturing in South Korea: Sub-Market Forecast, 2017-2027
7.13.1. Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, 2017-2027
7.13.2. Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, 2017-2027
 
7.14. Biopharmaceutical Contract Manufacturing in Australia
7.14.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario
7.14.2. Challenges Faced by CMOs in Australia
7.15. Leading Biopharmaceutical CMOs in Australia
7.15.1. Cell Therapies
7.15.1.1. Company Overview
7.15.1.2. Services Portfolio
7.15.1.3. Manufacturing Facilities
7.15.1.4. Partnerships
7.15.1.5. Recent Developments
 
7.15.2. LuinaBio
7.15.2.1. Company Overview
7.15.2.2. Services Portfolio
7.15.2.3. Manufacturing Facilities
7.15.2.4. Partnerships
 
8. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING
8.1. Chapter Overview
8.2. Antibody Drug Conjugates
8.2.1. Introduction
8.2.1.1. Manufacturing Process
8.2.1.2. Key Technologies and Technology Providers
8.2.2. Pipeline Analysis
8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules
8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules
8.2.3. In-house Manufacturing Scenario
8.2.3.1. Challenges Faced by ADC Manufacturers
8.2.4. Contract Manufacturing Scenario
8.2.4.1. Types of Contract Services Providers
8.2.4.1.1. ADC CMOs: Companies Providing Linker Production Services
8.2.4.1.2. ADC CMOs: Companies Providing HPAPI / Cytotoxic Drug Production Services
8.2.4.1.3. ADC CMOs: Companies Providing Conjugation Services
8.2.4.1.4. ADC CMOs: Full Services Providers
8.2.5. Key Drivers of the Contract Manufacturing Market for ADCs
8.2.5.1. Emergence of Startups
8.2.5.2. Investments and Facility Expansions
8.2.5.3. Partnerships and Collaborations
 
8.3. Bispecific Antibodies
8.3.1. Introduction
8.3.1.1. The Bispecific Advantage
8.3.1.2. Classification of Bispecific Antibodies
8.3.2. Pipeline Analysis
8.3.3. Bispecific Antibody Based Technology Providers
8.3.4. Contract Manufacturing Scenario
 
8.4. Cell Therapy
8.4.1. Introduction
8.4.2. Current Market Landscape
8.4.3. Cell Therapy Manufacturing
8.4.3.1. Cell Therapy Manufacturing: Key Challenges and Growth Drivers
8.4.4. Types of Manufacturers
8.4.2. Contract Manufacturing Scenario
 
8.5. Gene Therapy
8.5.1. Introduction
8.5.2. Pipeline Analysis
8.5.3. Contract Manufacturing Scenario
 
9. CASE STUDY: OUTSOURCING OF BIOSIMILARS
9.1. Chapter Overview
9.2. Biosimilars: An Introduction
9.3. Biosimilars: Need for Outsourcing of Development and Manufacturing Operations
9.4. Impact of Biosimilars on the Global Contract Manufacturing Market
9.4.1. Pipeline Analysis
9.4.2. Regional Trends
9.4.3. Contract Services Providers
9.5. Biosimilars: Challenges Associated with Outsourcing
 
10. RECENT DEVELOPMENTS
10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing Market: Partnerships
10.2.1. Biopharmaceutical Contract Manufacturing Market: Growing Trend of Partnerships
10.2.2. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Partnership
10.3. Biopharmaceutical Contract Manufacturing Market: Recent Developments
10.3.1. Biopharmaceutical Contract Manufacturing Market: Growing Trend of Recent Developments
10.3.2. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Recent Development
10.4. Biopharmaceutical Contract Manufacturing Market: Funding Instances
10.5. Biopharmaceutical Contract Manufacturing Market: Technological Advances
10.5.1. Adoption of Single-use Technologies
10.5.2. Process Analytical Technologies
10.5.3. Continuous Processing
10.5.4. Quality by Design in Bio-processing
 
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Biopharmaceutical CMOs: Global Production Capacity
11.3.1. Analysis by Region
11.3.2. Analysis by Expression Systems
11.4. Conclusion
 
12. SURVEY ANALYSIS
12.1. Chapter Overview
12.1.1. Overview of Respondents
12.1.2. Designation of Respondents
12.2. Biologics Manufacturing Expertise
12.3. Scale of Manufacturing
12.4. Location of Production Facilities
12.5. Types of Expression Systems
12.6. Types of Bioreactors
12.7. Modes of Operation of Bioreactors
 
13. OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology
13.3. Overall Biopharmaceutical Contract Manufacturing Market, 2017-2027
13.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2017-2027
13.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2017-2027
13.4. Biopharmaceutical Contract Manufacturing Market, 2017-2027: Analysis by Expression Systems
13.5. Biopharmaceutical Contract Manufacturing Market, 2017-2027: Regional Distribution
 
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Conclusion
 
15. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
15.1. Chapter Overview
15.2. Significant Growth in Outsourcing Activities
15.3. Evident Shift from One-time Contracts to Strategic Partnerships
15.4. New Technologies and Focus on Innovation to Support Further Growth in this Domain
15.5. Focus on Niche Therapeutic Areas to Sustain Growth
15.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
15.7. CMOs are Increasingly Expanding their Capabilities and Expertise in Order to become One Stop Shops
15.8. Offshoring of Outsourcing Activities to Maximize Profits and Expand Existing Capacities
15.9. Growing Demand for Biologics and Biosimilars to Influence Financial Inflow and Outsourcing Budgets
15.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies
15.11. Despite the Positive Future Outlook, There are a Number of Challenges Faced by both Sponsors and Service Providers
15.12. Concluding Remarks
 
16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
16.3. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
16.4. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
16.5. Dietmar Katinger, CEO, Polymun Scientific
16.6. Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
16.7. Mark Wright, Site Lead, Grangemouth, Piramal Healthcare
16.8. Raquel Fortunato, CEO, GenIbet Biopharmaceuticals
16.9. Sebastian Schuck, Head of Business Development, Wacker Biotech
16.10. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
16.11. Tim Oldham, CEO, Cell Therapies
16.12. Anonymous
 
17. APPENDIX I TABULATED DATA
 
18. APPENDIX II LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Types of Third Party Service Providers
Figure 3.2  Biopharmaceutical Contract Manufacturing: Commonly Outsourced Operations
Figure 4.1  Biopharmaceutical CMOs: Geographical Distribution of Facilities
Figure 4.2  Biopharmaceutical CMOs: Geographical Distribution of Facilities by Major  Regions
Figure 4.3  Biopharmaceutical CMOs: Distribution by Types of Biologics
Figure 4.4  Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.5  Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 4.6  Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Figure 4.7  Biopharmaceutical CMOs: Distribution by Modes of Operation of Bioreactors
Figure 5.1  Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and  Challenges
Figure 5.2  AMRI: Services Portfolio
Figure 5.3  AMRI Annual Revenues, FY 2012-FY 2016 (USD Million)
Figure 5.4  AMRI: Revenues by Business Divisions, FY 2016 (USD Million)
Figure 5.5  Baxter International: Annual Revenues, FY 2012-FY 2016 (USD Million)
Figure 5.6  Catalent: Services Portfolio
Figure 5.7  Catalent: Annual Revenues, FY 2012-FY 2016 (USD Million)
Figure 5.8  Catalent: Revenues by Business Divisions, FY 2016 (USD million)
Figure 5.9  Cytovance: Services Portfolio
Figure 5.10  Patheon: Services Portfolio
Figure 5.11  Patheon Services and Solutions: Biologics
Figure 5.12  Patheon Services and Solutions: Small Molecules
Figure 5.13  Patheon: Annual Revenues, FY 2012-Q1 2017 (USD Million)
Figure 5.14  Patheon: Revenues by Business Divisions, FY 2016 (USD Million)
Figure 5.15  Biopharmaceutical Contract Manufacturing in the US: Distribution by Type of  Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 5.16  Biopharmaceutical Contract Manufacturing in the US: Distribution  by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 6.1  Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 6.2  3P Biopharmaceuticals: Services Portfolio
Figure 6.3  Boehringer Ingelheim BioXcellence: Services Portfolio
Figure 6.4  Boehringer Ingelheim: Annual Revenues, FY 2012-FY 2016 (EUR Million) 
Figure 6.5  Boehringer Ingelheim: Revenues by Business Divisions, FY 2016 (EUR Million)
Figure 6.6  Celonic: Services Portfolio
Figure 6.7  FUJIFILM Diosynth Biotechnologies: Services Portfolio
Figure 6.8  FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2012- Q1-Q3 2017  (JPY Billion) 
Figure 6.9  FUJIFILM Holdings: Revenues by Business Divisions, FY 2016 (JPY Billion)
Figure 6.10  LFB Group: Services Portfolio
Figure 6.11  CELLforCURE: Services Portfolio
Figure 6.12  LFB Biomanufacturing Services: Services Portfolio
Figure 6.13  LFB Group: Annual Revenues, FY 2012-FY 2016 (EUR Million)
Figure 6.14  LFB Group: Revenues by Therapeutic Area and Services, FY 2016 (EUR Million)
Figure 6.15  Lonza: Services Portfolio
Figure 6.16  Lonza: Annual Revenues, FY 2012-FY 2016 (CHF Million)
Figure 6.17  Lonza: Revenues by Business Divisions, FY 2016 (CHF Million)
Figure 6.18  Menarini Biotech: Services Portfolio
Figure 6.19  Novasep: Services Portfolio 
Figure 6.20  Rentschler Biotechnologie: Services Portfolio
Figure 6.21  Biopharmaceutical Contract Manufacturing in Europe: Distribution by  Country, Base Scenario, 2017-2027 (USD Billion)
Figure 6.22  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of   Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 6.23  Biopharmaceutical Contract Manufacturing in Europe: Distribution by  Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.1  Biopharmaceutical Contract Manufacturing in China: Growth Drivers and  Challenges
Figure 7.2  Autotek Bio: Services Portfolio
Figure 7.3  Autotek Bio: DisposUp® Technology
Figure 7.4  WuXi Biologics: Services Portfolio
Figure 7.5  WuXi Biologics: Antibody Discovery Procedure
Figure 7.6  Biopharmaceutical Contract Manufacturing in China: Distribution by Type of  Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.7  Biopharmaceutical Contract Manufacturing in China: Distribution  by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.8  Biopharmaceutical Contract Manufacturing in India: Growth Drivers and  Challenges
Figure 7.9  Intas Pharmaceuticals: Revenues from Operations, FY 2012-FY 2016 (INR  Million)
Figure 7.10  Piramal Pharma Solutions: Annual Revenues, FY 2012-FY 2016 (INR Million)
Figure 7.11  Shasun Pharma: Revenues by Geography, FY 2015-FY 2016 (INR Billion)
Figure 7.12  Syngene: Services Portfolio
Figure 7.13  Syngene: Annual Revenues, FY 2012-Q1 2017 (INR Million)
Figure 7.14  Biopharmaceutical Contract Manufacturing in India: Distribution by Type of  Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.15  Biopharmaceutical Contract Manufacturing in India: Distribution by Expression  Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.16  Asahi Glass: Services Portfolio
Figure 7.17  Asahi Glass: Annual Revenues, FY 2012-Q1 2017 (JPY Million)
Figure 7.18  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of   Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.19  Biopharmaceutical Contract Manufacturing in Japan: Distribution by  Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.20  DMBio: Services Portfolio
Figure 7.21  DMBio: Manufacturing Services
Figure 7.22  Samsung BioLogics: Services Portfolio
Figure 7.23  Samsung BioLogics: Annual Revenues from CMO Operations, FY 2013-Q1  2017 (KRW Billion)
Figure 7.24  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by  Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.25  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by  Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.26  Cell Therapies: Cell Therapy Services
Figure 7.27  Luina Bio: Services Portfolio
Figure 8.1  Bispecific Antibodies Pipeline: Distribution by Phase of Development
Figure 8.2  Cell Therapy Manufacturing: Key Steps
Figure 8.3  Cell Therapy: Key Challenges and Growth Drivers
Figure 8.4  Cell Therapy Manufacturing: Types of Manufacturers
Figure 8.5  Gene Therapy Pipeline: Distribution by Phase of Development
Figure 8.6  Gene Therapy Contract Manufacturers: Distribution by Scale of Operation
Figure 8.7  Gene Therapy Contract Manufacturers: Distribution by Location
Figure 9.1  Global Biosimilars Pipeline: Distribution by Phase of Development
Figure 9.2  Global Biosimilars Pipeline: Distribution by Phase of Development and Product  Category
Figure 9.3  Global Biosimilars Pipeline: Distribution by Phase of Development and  Geography
Figure 10.1  Biopharmaceutical Contract Manufacturing Market: Cumulative Trend of  Partnerships
Figure 10.2  Biopharmaceutical Contract Manufacturing Market: Distribution by Type of  Partnership
Figure 10.3  Biopharmaceutical Contract Manufacturing Market: Cumulative Trend of  Recent Developments
Figure 10.4  Biopharmaceutical Contract Manufacturing Market: Distribution by Type of  Recent Development
Figure 10.5  Process Analytical Technologies: Key Advantages
Figure 10.6  Continuous Processing: Key Advantages
Figure 11.1  Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
Figure 11.2 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs (Small  and Mid-sized CMOs)
Figure 11.3  Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs  (Small and Mid-sized CMOs)
Figure 11.4  Capacity Analysis: Regional Contract Biomanufacturing Capacity (Small and  Mid-sized CMOs)
Figure 11.5  Capacity Analysis: Percentage Distribution by Expression Systems Used
Figure 12.1  Survey Analysis: Distribution of Respondents by Company Type
Figure 12.2  Survey Analysis: Distribution of Respondents by Location of Headquarters
Figure 12.3  Survey Analysis: Distribution of Respondents by Designation
Figure 12.4  Survey Analysis: Distribution by Biologics Manufacturing Expertise
Figure 12.5  Survey Analysis: Distribution by Scale of Manufacturing
Figure 12.6  Survey Analysis: Distribution by Location of Production Facilities
Figure 12.7  Survey Analysis: Distribution by Types of Expression Systems
Figure 12.8  Survey Analysis: Distribution by Types of Bioreactors
Figure 12.9  Survey Analysis: Distribution by Modes of Operation of Bioreactors
Figure 13.1  Biopharmaceutical Contract Manufacturing Market: Share of Contract  Manufacturers
Figure 13.2  Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base  Scenario (USD Billion)
Figure 13.3  Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027:  Base Scenario (USD Billion)
Figure 13.4  Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027:  Base Scenario (USD Billion)
Figure 13.5  Distribution of Global Biopharmaceutical Contract Manufacturing Market by  Expression Systems, 2017-2027: Base Scenario (USD Billion)
Figure 13.6  Regional Distribution of Biopharmaceutical Contract Manufacturing Market,  2017-2027: Base Scenario (USD Billion)
Figure 14.1  Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002- 2016

List of Tables

Table 4.1  Biopharmaceutical CMOs: Geographical Presence
Table 4.2  Biopharmaceutical CMOs: Types of Biologics
Table 4.3  Biopharmaceutical CMOs: Scale of Operation
Table 4.4  Biopharmaceutical CMOs: Types of Expression Systems
Table 4.5 Biopharmaceutical CMOs: Types of Bioreactors
Table 4.6  Biopharmaceutical CMOs: Modes of Operation
Table 4.7  Biopharmaceutical CMOs: Contract Biomanufacturing Capacity
Table 4.8  Biopharmaceutical CMOs: Types of Packaging Forms
Table 5.1  Catalent: Biopharmaceutical Facilities
Table 5.2  Patheon: Biopharmaceutical Facilities
Table 6.1  FDA Quality Agreement versus EMA cGMP Regulations: A Comparative  Analysis 
Table 6.2  Boehringer Ingelheim BioXcellence: Biopharmaceutical Facilities
Table 6.3  Celonic: Biopharmaceutical Facilities 
Table 6.4  FUJIFILM Diosynth Biotechnologies: Biomanufacturing Capabilities
Table 6.5  Lonza: Biopharmaceutical Facilities 
Table 7.1  Intas Pharmaceuticals: Biopharmaceutical Facilities 
Table 7.2  Kemwell Biopharma: Biopharmaceutical Facilities 
Table 7.3  Piramal Pharma Solutions: Biopharmaceutical Facilities 
Table 7.4  Shasun Pharma: Biopharmaceutical Facilities
Table 7.5  Samsung BioLogics: Biopharmaceutical Facilities
Table 8.1  ADC Pipeline: Marketed and Clinical Molecules 
Table 8.2  ADC Pipeline: Preclinical and Discovery Stage Molecules
Table 8.3  ADC Contract Manufacturers: Overview of Capabilities
Table 8.4  ADC Contract Manufacturers: Conjugation Services Providers
Table 8.5  ADC Contract Manufacturers: Full Services CMOs
Table 8.6  Bispecific Antibodies Pipeline
Table 8.7  Bispecific Antibody Technologies and Technology Providers
Table 8.8  Cell Therapies: Applications
Table 8.9  Cell Therapies: Commercialized Products
Table 8.10  Cell Therapy Manufacturing: Assessment Strategies for Different Manufacturing  Processes
Table 8.11  Cell Therapy Contract Manufacturers
Table 8.12  Gene Therapy Contract Manufacturers
Table 9.1  Contract Services Providers for Biosimilars
Table 10.1  Biopharmaceutical Contract Manufacturing Market: Partnerships
Table 10.2  Biopharmaceutical Contract Manufacturing Market: Recent Developments
Table 10.2  Biopharmaceutical Contract Manufacturing Market: Funding Instances
Table 11.1  Capacity Analysis: CMO Size Adjustments based on Capacity
Table 11.2  Capacity Analysis: CMO Size Adjustments based on Employee Base
Table 11.3  Capacity Analysis: Average Capacity per Category
Table 11.4  Capacity Analysis: Global Contract Biomanufacturing Capacity 
Table 11.4  Capacity Analysis: Regional Contract Biomanufacturing Capacity (Small and  Mid-sized CMOs)
Table 12.1  Survey Analysis: Overview of Respondents
Table 12.2  Survey Analysis: Distribution of Respondents by Designation
Table 12.3  Survey Analysis: Biologics Manufacturing Expertise
Table 12.4  Survey Analysis: Scale of Manufacturing
Table 12.5  Survey Analysis: Location of Production Facilities
Table 12.6  Survey Analysis: Types of Expression Systems
Table 12.7  Survey Analysis: Types of Bioreactors
Table 12.8  Survey Analysis: Modes of Operation of Bioreactors
Table 14.1 Biopharmaceutical Contract Manufacturing Market: SWOT Analysis
Table 14.2  Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best- selling Biologics
Table 17.1  Biopharmaceutical CMOs: Geographical Distribution of Facilities
Table 17.2  Biopharmaceutical CMOs: Geographical Distribution of Facilities by Major Regions
Table 17.3  Biopharmaceutical CMOs: Distribution by Types of Biologics
Table 17.4  Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 17.5  Biopharmaceutical CMOs: Distribution by Expression Systems
Table 17.6  Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Table 17.7  Biopharmaceutical CMOs: Distribution by Modes of Operation
Table 17.8  AMRI Annual Revenues, FY 2012-Q1 2017 (USD Million)
Table 17.9  AMRI: Revenues by Business Segments, FY 2016 (USD Million)
Table 17.10  Baxter International: Revenues, FY 2012 – Q1 2017 (USD Million)
Table 17.11  Catalent: Revenues, FY 2012 – Q1-Q3 2017 (USD Million)
Table 17.12  Catalent: Revenues by Business Divisions, FY 2016 (USD Million)
Table 17.13  Patheon: Annual Revenues, FY 2012 – Q1 2017 (USD Million)
Table 17.14  Patheon: Revenues by Business Segments, FY 2016 (USD Million)
Table 17.15  Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.16  Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.17  Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.18  Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.19  Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.20  Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.21  Boehringer Ingelheim: Annual Revenues, FY 2012 – FY 2016 (EUR Million)
Table 17.22  Boehringer Ingelheim: Revenues by Business Divisions, FY 2016 (EUR Million)
Table 17.23  FUJIFILM Group: Revenues, FY 2012 – Q1-Q3 2017 (JPY Billion)
Table 17.24  FUJIFILM Holdings: Revenue by Business Divisions, FY 2016 (JPY Billion)
Table 17.25  LFB Group: Annual Revenues, FY 2012 – FY 2015 (EUR Million)
Table 17.26  LFB Group: Revenues by Therapeutic Area and Services, FY 2015 (EUR Million)
Table 17.27  Lonza: Annual Revenues, FY 2012 – FY2016 (CHF Million)
Table 17.28  Lonza: Revenues by Business Divisions, 2016 (CHF Million)
Table 17.29  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.30  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Base Scenario, 2017-2027 (USD Billion)
Table 17.31  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.32  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.33  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.34  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.35  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.36  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.37  Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.38  Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.39  Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.40  Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.41  Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.42  Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.43  Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.44  Intas Pharmaceuticals: Revenue from Operations, FY 2012 – FY 2016 (INR Million)
Table 17.45  Piramal Pharma Solutions: Annual Revenues, FY 2012- FY 2016 (INR Million)
Table 17.46  Shasun Pharma: Revenues by Geography, FY 2015-FY 2016 (INR Billion)
Table 17.47  Syngene: Annual Revenues FY 2012-Q1 2017 (INR Million)
Table 17.48  Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.49  Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.50  Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.51  Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.52  Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.53  Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.54  Asahi Glass Company: Annual Revenues, FY 2012-Q1 2017 (JPY Million)
Table 17.55  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.56  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.57  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.58  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.59  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.60  Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.61  Samsung BioLogics: Revenues from CMO, FY 2013-Q1 2017 (KRW Billion)
Table 17.62  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.63  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.64  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.65  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.66  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.67  Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.68  Bispecific Antibodies Pipeline: Distribution by Phase of Development
Table 17.69  Gene Therapy Pipeline: Distribution by Phase of Development
Table 17.70  Gene Therapy Contract Manufacturers: Distribution by Scale of Operation
Table 17.71  Gene Therapy Contract Manufacturers: Distribution by Location
Table 17.72  Global Biosimilars Pipeline: Distribution by Phase of Development
Table 17.73  Global Biosimilars Pipeline: Distribution by Phase of Development and Product  Category
Table 17.74 Global Biosimilars Pipeline: Distribution by Phase of Development and  Geography
Table 17.75  Biopharmaceutical CMOs: Cumulative Investment by Year
Table 17.76  Biopharmaceutical CMOs Investments: Distribution by Type
Table 17.77  Biopharmaceutical CMOs Partnerships: Distribution by Type of Partnerships
Table 17.78  Biopharmaceutical CMOs Partnerships: Cumulative Distribution by Year
Table 17.79  Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
Table 17.80  Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
Table 17.81  Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs
Table 17.82  Capacity Analysis: Regional Contract Biomanufacturing Capacity
Table 17.83  Capacity Analysis: Percentage Distribution by Expression Systems Used
Table 17.84  Survey Analysis: Distribution of Respondents by Company Type
Table 17.85  Survey Analysis: Distribution of Respondents by Location of Headquarters
Table 17.86  Survey Analysis: Distribution of Respondents by Designation
Table 17.87  Survey Analysis: Distribution by Biologics Manufacturing Expertise
Table 17.88  Survey Analysis: Distribution by Scale of Manufacturing
Table 17.89  Survey Analysis: Distribution by Location of Production Facilities
Table 17.90  Survey Analysis: Distribution by Types of Expression Systems
Table 17.91  Survey Analysis: Distribution by Types of Bioreactors
Table 17.92  Survey Analysis: Distribution by Modes of Operation of Bioreactors
Table17.93  Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Conservative Scenario (USD Billion)
Table 17.94  Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
Table 17.95  Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.96  Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Conservative Scenario (USD Billion)
Table 17.97  Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Base Scenario (USD Billion)
Table 17.98  Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.99 Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Conservative Scenario (USD Billion)
Table 17.100  Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Base Scenario (USD Billion)
Table 17.101  Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.102  Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Conservative Scenario (USD Billion)
Table 17.103  Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Base Scenario (USD Billion)
Table 17.104  Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.105  Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Conservative Scenario (USD Billion)
Table 17.106  Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
Table 17.107  Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.108  Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Conservative Scenario (USD Billion)
Table 17.109 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Base Scenario (USD Billion)
Table 17.110  Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Optimistic Scenario (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. 3P Biopharmaceuticals
  2. Aalto Scientific
  3. AbbVie Contract Manufacturing
  4. AbGenomics
  5. Ablynx
  6. Abzena
  7. ACES Pharma
  8. Acticor Biotech
  9. Active Biotech
  10. Adar Biotech
  11. ADC Therapeutics
  12. Adimab
  13. Advanced BioScience Laboratories (ABL)
  14. Advanced Biotherapeutics Consulting (ABC)
  15. Affimed
  16. Affinity Life Sciences
  17. Agensys
  18. Ajinomoto Althea
  19. Albany Molecular Research (AMRI)
  20. Alberta Cell Therapy Manufacturing
  21. Alcami
  22. Aldevron
  23. Allele Biotechnology
  24. Alliance Medical Products  
  25. Alligator Bioscience
  26. Allozyne
  27. ALMAC Group
  28. Altaris Capital Partners
  29. AmatsiQBiologicals
  30. AmbioPharm
  31. Ambrx
  32. AmBTU
  33. AMEGA Biotech
  34. Amgen
  35. Amneal Life Sciences
  36. AMSBIO
  37. Anogen
  38. apceth Biopharma 
  39. Applied Biological Materials
  40. Applied Viromics
  41. Aptuit
  42. Arabio
  43. Asahi Glass
  44. Aspyrian Therapeutics 
  45. Astellas Pharma 
  46. AstraZeneca
  47. Asymchem
  48. Athenex Pharma Solutions
  49. Atlantic Bio GMP
  50. AURA Biotechnologies
  51. AUSTRIANOVA
  52. AutekBio
  53. Avecia
  54. Avid Biologics
  55. Avid Bioservices
  56. Bachem 
  57. Baliopharm
  58. Batavia Biosciences
  59. Baxter BioPharma Solutions
  60. Bayer
  61. BCN Peptides
  62. Beckman Research Institute
  63. Beijing ABT Genetic Engineering Technology
  64. Bharat Serums And Vaccines
  65. BIBITEC
  66. Bicycle Therapeutics
  67. BINEX
  68. Bio Elpida
  69. Bioanalytical Sciences Department, Southern Research
  70. BioCell 
  71. Biocon
  72. BioConnection
  73. Biofabri
  74. Biogen-Idec
  75. BioLineRx
  76. Biological and Cellular GMP Manufacturing Facility, City of Hope
  77. Biological E
  78. Biological Process Development Facility, University of Nebraska
  79. BioMARC
  80. Biomatik
  81. Biomay
  82. BIOMEVA
  83. BiondVax Pharmaceuticals 
  84. BioPharmaceuticals Australia
  85. Biosynergy
  86. Bio-Synthesis
  87. BioTechLogic 
  88. BioTechnique
  89. Biotechpharma
  90. Biotecnol
  91. Biotest
  92. BioVectra
  93. Biovian
  94. Blue Stream Laboratories
  95. Boehringer Ingelheim
  96. Boehringer Ingelheim BioXcellence 
  97. Brammer Bio
  98. Bristol-Myers Squibb
  99. Bryllan
  100. BSP Pharmaceuticals
  101. Cambrex 
  102. CARBOGEN AMCIS
  103. Catalent
  104. Catalent Biologics
  105. Catalent Pharma Solutions 
  106. Cedarburg Pharmaceuticals 
  107. Celgene
  108. Cell and Gene Therapy Catapult
  109. Cell Culture Company
  110. Cell Essentials
  111. Cell Therapies
  112. Cell Therapy and Regenerative Medicine, University of Utah
  113. Celldex Therapeutics
  114. CELLforCURE
  115. Cellin Technologies
  116. Cells for Sight, Stem Cell Therapy Research Unit, University College London 
  117. Celltrion
  118. Cellular Dynamics International (a FUJIFILM company)
  119. Cellular Therapeutics
  120. Cellular Therapy Integrated Service, Case Western Reserve University
  121. Celonic
  122. Center for Biocatalysis and Bioprocessing, University of Iowa
  123. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  124. Center for Cell and Gene Processing, Takara Bio
  125. Center for Cell and Gene Therapy, Baylor College of Medicine
  126. Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia  (CHOP)
  127. Center of iPS Cell Research and Application, Kyoto University (CiRA)
  128. Centre for Commercialization of Regenerative Medicine 
  129. Centrose 
  130. Century Pharmaceuticals
  131. Cerbios-Pharma
  132. CEVEC Pharmaceuticals
  133. Charles River Laboratories
  134. ChemCon
  135. Chemi Peptides
  136. ChemPartner
  137. Children's GMP / GMP facility St. Jude Children's Research Hospital
  138. ChromaCon 
  139. Cincinnati Children's Hospital Medical Center
  140. CinnaGen
  141. Clinical Biomanufacturing Facility, University of Oxford
  142. Clinical Research Facility, South London and Maudsley
  143. CMC Biologics
  144. Cobra Biologics
  145. Cognate BioServices
  146. Coldstream Laboratories
  147. Concord Biotech
  148. Concortis
  149. Cook Pharmica 
  150. Corden Pharma
  151. Covance
  152. Creative Biogene
  153. Creative Biolabs
  154. Cryosite
  155. CytomX Therapeutics
  156. Cytovance Biologics
  157. Daiichi Sankyo
  158. Dalton Pharma Services
  159. Dishman Group
  160. DMBio
  161. Dow Pharmaceutical Solutions
  162. Dutalys
  163. EirGenix
  164. Eli Lilly
  165. Embio
  166. EMD Serono
  167. Emergent BioSolutions
  168. Emerson
  169. Encap Drug Delivery
  170. Endo Pharmaceuticals
  171. Epigen Biotech
  172. Esperance Pharmaceuticals
  173. EuBiologics
  174. EUCODIS Bioscience
  175. EUFETS
  176. Eurofins Central Global Laboratory
  177. Eurogentec
  178. Euticals
  179. Evonik
  180. Fabion Pharmaceuticals
  181. Ferro Pfanstiehl
  182. FinVector
  183. Formation Biologics
  184. Formosa Laboratories
  185. Foundation BioPharma 
  186. Fraunhofer Institute for Cell Therapy and Immunology IZI
  187. French National Centre for Scientific Research, Université de Toulouse
  188. Frontage Laboratories
  189. F-star
  190. FUJIFILM Diosynth Biotechnologies
  191. Fusimab
  192. Fusion Antibodies
  193. Gadea Pharmaceutical Group 
  194. Gala Biotech
  195. Gallus BioPharmaceuticals
  196. Ganymed Pharmaceuticals
  197. Gates Biomanufactuirng Facility
  198. GE Healthcare
  199. GEG Tech
  200. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  201. Gene Medicine Japan / Kobe Biomedical Accelerator
  202. Gene Transfer Vector Core (GTVC)
  203. Gene Transfer Vector Core, Schepens Eye Research Institute and Massachusetts Eye and  Ear Infirmary
  204. Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
  205. Gene Vector and Virus Core, Stanford Medicine
  206. GeneCure Biotechnologies
  207. GeneDetect
  208. Genentech
  209. Genethon
  210. GenIbet Biopharmaceuticals
  211. Genmab
  212. Génopoïétic
  213. GenVec 
  214. Gilead Sciences
  215. GIPharma
  216. Glenmark Pharmaceuticals
  217. Glycotope Biotechnology
  218. GNH India
  219. Goodwin Biotechnology
  220. GOSH Cellular Therapy Laboratories, University College of London
  221. GP Pharm
  222. Grand River Aseptic Manufacturing
  223. Great Point Partners
  224. GreenPak Biotech 
  225. Grünenthal
  226. GSEx, The Robinson Research Institute, University of Adelaide
  227. GSK
  228. GSK-Domantis
  229. GTP Technology
  230. Guy's and St Thomas' Facility
  231. HALIX 
  232. Harvest Moon Pharmaceuticals
  233. Health Biotech
  234. Health Sciences Authority
  235. Heidelberg Pharma
  236. Hepalink 
  237. Hetero Drugs
  238. Histocell
  239. Hisun Pharmaceuticals USA
  240. Ho Research Consortium
  241. Hong Kong Institute of Biotechnology
  242. Hope Center Viral Vectors Core, Washington University School of Medicine
  243. iBIOSOURCE
  244. Icagen
  245. IDDI
  246. IDT Biologika
  247. Igenica Biotherapeutics
  248. ImClone Systems 
  249. ImmunoGen
  250. Immunomedics
  251. INC Research
  252. Indian Immunologicals
  253. Inhibrx
  254. Inno Biologics 
  255. Innovent Biologics
  256. Intas Pharmaceuticals
  257. Integrity Bio
  258. International Joint Cancer Institute, Military Medical University
  259. Intertek
  260. Istituto Biochimico Italiano Giovanni Lorenzini
  261. JHL Biotech
  262. John Goldmann Centre for Cellular Therapy, Imperial College London
  263. Julphar Gulf Pharmaceutical Industries
  264. KABS Pharmaceutical Services 
  265. Kairos Therapeutics
  266. Kamat Pharmatech
  267. KBI Biopharma
  268. Kemwell Biopharma
  269. Laboratory for Cell and Gene Medicine, Stanford University 
  270. LAMPIRE Biological Laboratories
  271. Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec)
  272. LFB BIOMANUFACTURING
  273. Lindis Biotech 
  274. Lonza
  275. LuinaBio
  276. MabPlex
  277. MacroGenics
  278. Maine Biotechnology Services
  279. MassBiologics
  280. MaSTherCell
  281. MBI International
  282. MediaPharma
  283. MedImmune
  284. Medix Biochemica
  285. Menarini Biotech
  286. Merck
  287. Meridian Life Science
  288. Merrimack
  289. Merro Pharmaceutical
  290. Mersana Therapeutics
  291. Merus
  292. MGH Vector Core (Massachusetts General Hospital Neuroscience Center)
  293. MicroBiopharm Japan
  294. Microbix Biosystems
  295. Millennium Pharmaceuticals
  296. Minomic International
  297. Mitsubishi Gas Chemical Company
  298. Moderna Therapeutics
  299. Molecular and Cellular Therapeutics, University of Minnesota
  300. Molecular Partners
  301. MolMed
  302. MPI Research
  303. Multispan
  304. Mycenax Biotech
  305. Nantes Gene Therapy Institute 
  306. Nascent Biologics 
  307. National Cancer Institute (NCI)
  308. National Research Council of Canada
  309. NBE Therapeutics
  310. Neuland Laboratories
  311. NeuroCure (Viral Core Facility)
  312. NeuroFx
  313. Newcastle Cellular Therapies, University of Newcastle 
  314. NextCell
  315. NHS Blood and Transplant
  316. NHSBT Birmingham 
  317. Nikon Cell And Gene Therapy Contract Manufacturing
  318. Nitto Avecia Pharma Services
  319. Nordic Nanovector
  320. Norwegian Institute of Public Health
  321. Nova Laboratories
  322. Novartis
  323. Novasep
  324. Novex Innovations
  325. NovImmune
  326. Numab
  327. Oasmia Pharmaceutical 
  328. OcellO
  329. OctoPlus
  330. Okairos (GSK subsidiary)
  331. Olon
  332. Omnia Biologics
  333. OncoMed
  334. OncoQuest
  335. OsoBio
  336. OXB Solutions (a business of Oxford BioMedica) 
  337. Oxford BioMedica
  338. Oxford BioTherapeutics
  339. Oxford Genetics 
  340. Pacific GMP
  341. Paktis Antibody Services
  342. Palatin Technologies
  343. Pamlico BioPharma
  344. Panacea Biotec
  345. Paragon Bioservices
  346. Parexel
  347. Particle Sciences
  348. PATH
  349. Patheon
  350. PCI Services (Biotec Services International)
  351. PCT, a Caladrius company
  352. Penn Vector Core, University of Pennsylvania
  353. Pfizer
  354. Pfizer CentreOne
  355. PharmAbcine
  356. PharmaBio
  357. PharmaCell
  358. Pharmedartis
  359. PharmiCell
  360. Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  361. Philochem
  362. PhotoBiotics
  363. Pierre Fabre
  364. Piramal Pharma Solutions
  365. PlasmidFactory
  366. Polymun Scientific
  367. Polypeptide Group
  368. Praxis Pharmaceutical
  369. Precision Antibody
  370. Precision Biologics
  371. PREMAS Biotech
  372. ProBioGen
  373. Productos Bio-Logicos
  374. Profectus BioSciences
  375. Progenics Pharmaceuticals
  376. ProJect Pharmaceutics
  377. ProMab Biotechnologies
  378. Protheragen
  379. Provantage End-to-End Services (Merck Millipore)
  380. PX'Therapeutics
  381. Pyramid Labs
  382. Quintiles
  383. Raymond G Perelman Center for Cellular and Molecular Therapeutics, The Children's  Hospital of Philadelphia
  384. Rayne's Cell Therapy Suite, King's College London
  385. Receptor Logic
  386. Redwood Bioscience
  387. Regeneron Pharmaceuticals
  388. Reliance Life Sciences
  389. Rentschler Biotechnologie
  390. Research and Development Center for Cell Therapy, Foundation for Biomedical  Research and Innovation
  391. Richter-Helm BioLogics
  392. Rimedion
  393. Robertson Clinical and Translational Cell Therapy, Duke University
  394. Roche
  395. Roslin Cell Therapies 
  396. Roswell Park Cancer Institute
  397. Royal DSM 
  398. Royal Free, CCGTT 
  399. SAB Technology
  400. SAFC
  401. Samsung BioLogics
  402. Sandoz
  403. Sanofi, CEPiA (Commercial & External Partnership, Industrial Affairs)
  404. Sanofi-Aventis 
  405. Sanquin Pharmaceutical Services
  406. School of Medicine, University of Utah
  407. Scientific Protein Laboratories
  408. Sea Lane Biotechnologies
  409. Seattle Genetics
  410. Selexys Pharmaceuticals
  411. Senn Chemicals
  412. SGS Life Science Services
  413. Shire
  414. SignaGen Laboratories
  415. Singota Solutions
  416. Sirion Biotech
  417. SNBTS Cellular Therapy Facility
  418. Societa Italiana Corticosteroidi
  419. Sorrento Therapeutics
  420. Spirogen
  421. ST Pharm
  422. Stem CentRx
  423. Sutro Biopharma 
  424. Sydney Cell and Gene Therapy 
  425. Symbiosis Pharmaceutical Services
  426. Symbiosis, the Analytical Company
  427. SynCo Bio Partners
  428. Synergys Biotherapeutics
  429. Syngene
  430. SYNIMMUNE
  431. Synthon
  432. Sypharma
  433. System Biosciences
  434. Takara Bio
  435. Takeda
  436. The Chemistry Research Solution
  437. The Lentiviral Laboratory, USC School of Pharmacy
  438. The Native Antigen Company
  439. The Vector Core, University of North Carolina
  440. Therapure Biopharma (Therapure Biomanufacturing)
  441. THERAVECTYS
  442. Thermo Fisher Scientific
  443. Toyobo Biologics 
  444. Translational Sciences
  445. TranXenoGen
  446. Trenzyme
  447. Trion Pharma
  448. Triphase Accelerator Corporation
  449. UC Davis GMP Laboratory
  450. UCB-Celltech
  451. UCLA Human Gene and Cell Therapy
  452. UMN Pharma
  453. University of Alabama Fermentation Facility
  454. University of Manchester 
  455. University of Oxford Clinical BioManufacturing Facility
  456. University of Texas
  457. Upstate Stem Cell cGMP Facility, University of Rochester
  458. Valerion Therapeutics
  459. Valneva
  460. Vectalys
  461. Vector Biolabs
  462. Vector Core / GMP Facility, UC Davis
  463. Vector Core Lab / Human Applications Lab, Powell Gene Therapy Center, University of  Florida
  464. Vector Core of Gene Therapy Laboratory of Nantes
  465. Vector Production Facility, Indiana University
  466. Vecura (Karolinska University Hospital )
  467. Vetter Pharma International
  468. VGXI
  469. Vibalogics
  470. Vigene Biosciences
  471. Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital
  472. Viral Vector Core, Duke University
  473. Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute
  474. Viral Vector Core, University of Iowa Carver College of Medicine
  475. Viral Vector Core, University of Massachusetts Medical School (UMMS)
  476. Virovek
  477. Vista Biologicals
  478. VIVEbioTECH
  479. Wacker Biotech
  480. Waisman Biomanufacturing
  481. WIL Research
  482. Wockhardt 
  483. Wolfson Gene Therapy Unit, University College of London
  484. WuXi AppTec
  485. Wyeth
  486. X-BODY Biosciences
  487. Xellbiogene
  488. Xencor
  489. YposKesi
  490. Zhejiang HISUN Pharmaceuticals
  491. Zhengyang Gene Technology
  492. Zumutor Biologics 
  493. Zydus Cadila
  494. Zymeworks
  495. ZymoGenetics
  496. Zyngenia

PRICING DETAILS

USD 2,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.